Effect of chronic antipsychotic drug treatment on preprosomatostatin and preprotachykinin A mRNA levels in the medial prefrontal cortex, the nucleus accumbens and the caudate putamen of the rat

Molecular Brain Research

Volumn 45, Issue 2, 1997, Pages 275-282

  Marcus, Monica M ^a   Nomikos, George G ^a   Malmerfelt, Anna ^a   Zachrisson, Olof ^a   Lindefors, Nils ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Amperozide; Antidepressant drug; Clozapine; Haloperidol; Raclopride; Serotonin; Somatostatin; Substance P

Indexed keywords

AMPEROZIDE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; HORMONE PRECURSOR; MESSENGER RNA; NEUROLEPTIC AGENT; PREPROTACHYKININ; RACLOPRIDE; SOMATOSTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CAUDATE NUCLEUS; CELL DENSITY; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; IN SITU HYBRIDIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEUROENDOCRINE SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CAUDATE NUCLEUS; CLOZAPINE; DOPAMINE ANTAGONISTS; HALOPERIDOL; MALE; NUCLEUS ACCUMBENS; ORGAN SPECIFICITY; PIPERAZINES; PREFRONTAL CORTEX; PROTEIN PRECURSORS; PUTAMEN; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SALICYLAMIDES; SOMATOSTATIN; TACHYKININS; TRANSCRIPTION, GENETIC;

EID: 0031148562     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(96)00263-X     Document Type: Article

References (59)

1. Aguilar, M.A., Miñarro, J., Pérez-Iranzo, N. and Simón, V.M., Behavioral profile of raclopride in agonistic encounters between male mice, Pharmacol. Biochem. Behav., 47 (1994) 753-756.
2. Angulo, J.A., Christoph, G.R., Manning, R.W., Burkhart, B.A. and Davis, L.G., Reduction of dopamine receptor activity differentially alters striatal neuropeptide mRNA levels, Adv. Exp. Med. Biol., 221 (1987) 385-391.
3. Angulo, J.A., Cadet, J.L. and McEwen, B.S., Effect of typical and atypical neuroleptic treatment on protachykinin mRNA levels in the striatum of the rat, Neurosci. Lett., 113 (1990) 217-221.
4. Axelsson, R., Nilsson, A., Christensson, E. and Björk, A., Effects of amperozide in schizophrenia, Psychopharmacology, 104 (1991) 287-292.
5. Bannon, M.J., Lee, J.-M., Giraud, P., Young, A., Affolfer, H.-U. and Bonner, T.I., Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNAs in rat striatonigral neurons, J. Biol. Chem., 261 (1986) 6640-6642.
6. Bannon, M.J., Elliott, P.J. and Bunney, E.B., Striatal tachykinin biosynthesis: Regulation of mRNA and peptide levels by dopamine agonists and antagonists, Mol. Brain Res., 3 (1987) 31-37.
7. Beal, M.F. and Martin, J.B., Effects of neuroleptic drugs on brain somatostatin-like-immunoreactivity, Neurosci. Lett., 47 (1984) 125-130.
8. Bissette, G. and Myers, B., Minireview: Somatostatin in Alzheimer's disease and depression, Life Sci., 51 (1992) 1389-1410.
9. Björk, A., Bergman, I. and Gustavsson, G., Amperozide in the treatment of schizophrenic patients. A preliminary report. In H.Y. Meltzer (Ed.), Novel Antipsychotic Drugs, Raven, New York, 1992, pp. 47-57.
10. Conley, R.R., Schulz, S.C., Baker, R.W., Collins, J.F. and Bell, J.A., Clozapine efficacy in schizophrenic nonresponders, Psychopharmacol. Bull., 24 (1988) 269-274.
11. Coward, D.M., General pharmacology of clozapine, Br. J. Psychiatry, 160 (Suppl. 17) (1992), 5-11.
12. Deutch, A.Y., Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: Implications for schizophrenia and Parkinsson's disease, J. Neural Transm. - Gen. Sect., 91 (1993) 197-221.
13. Deutch, A.Y. and Cameron, D.S., Pharmacological characterization of dopamine system in the nucleus accumbens core and shell, Neuroscience, 46, (1992) 49-56.
14. 3 receptors on neurotensin mRNA expression in nucleus accumbens, Eur. J. Neurosci., 6 (1994) 1384-1387.
15. Epelbaum, J., Somatostatin in the central nervous system: physiology and pathological modifications, Prog. Neurobiol., 27 (1986) 63-100.
16. 2-dopamine receptor occupancy by PET, Psychopharmacology, 94 (1988) 1-7.
17. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine, Arch. Gen. Psychiatry, 49 (1992) 538-544.
18. 2-receptor occupancy in clozapine-treated patients, J. Clin. Psychiatry, 55 (Suppl. B) (1994) 67-69.
19. Ferré, S. and Artigas, F., Clozapine decreases serotonin extracellular levels in the nucleus acumbens by a dopamine receptor-independent mechanism, Neurosci. Lett., 187 (1995) 61-64.
20. Goodman, R.H., Aron, D.C. and Roos, B.A., Rat pre-prosomatostatin, J. Biol. Chem., 258 (1983) 5570-5573.
21. Gustafsson, B. and Christensson, E., Amperozide - a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour, Pharmacol. Toxicol. (Suppl. 1) (1990) 12-17.
22. Gustafsson, B. and Christensson, E., Amperozide and emotional behaviour, Pharmacol. Toxicol., (Suppl. 1) (1990) 34-39.
23. Hertel, P., Nomikos, G.G., Iurlo, M. and Svensson, T.H., Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain., Psychopharmacology, 124 (1996) 74-86.
24. Humpel, C., Knaus, G.A., Auer, B., Knaus, H.-G., Haring, C., Theodorsson, E. and Saria, A., Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato-nigral system, Synapse, 6 (1990) 1-9.
25. Kakigi, T., Maeda, K., Kaneda, H. and Chihara, K., Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain, J. Affect. Disorders, 25 (1992) 215-220.
26. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. and the Clozaril Collaborative Study Group, Clozapine for the treatment-resistant schizophrenic, Arch. Gen. Psychiatry, 45 (1988) 789-796.
27. 3H-raclopride. Biochem. Pharmacol., 34 (1985) 2251-2259.
28. Krause, J.E., Chirgwin, J.M., Carter, M.S., Xu, Z.S. and Hershey, A.D., Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A, Proc. Natl. Acad. Sci. USA, 84 (1987) 881-885.
29. Leysen, J.E. and Niemegeers, C.J.E., Neuroleptics. In A. Lajtha (Ed.), Handbook in Neurochemistry, Vol. 9, Plenum, New York, 1985, pp. 331-361.
30. Li, S.J., Sivam, S.P., McGinty, J.F., Huang, Y.S. and Hong, J.S., Dopaminergic regulation of tachykinin metabolism in the striatonigral pathways., J. Pharmacol. Exp. Ther., 243 (1987) 792-798.
31. Lindefors, N., Brodin, E. and Ungerstedt, U., Neuroleptic treatment induces region-specific changes in levels of neurokinin A and substance P in rat brain, Neuropeptides, 7 (1986) 265-280.
32. Lindefors, N., Amphetamine and haloperidol modulate preprotachykinin A mRNA expression in rat nucleus accumbens and caudate-putamen, Mol. Brain Res., 13 (1992) 151-154.
33. Marcus, M.M., Nomikos, G.G. and Svensson, T.H., Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens, Eur. Neuropsychopharmacol., 6 (1996) 29-38.
34. Mathé, A.A., Nomikos, G.G. and Svensson, T.H., Effects of acute and chronic electroconvulsive treatment on interstitial concentrations of somatostatin in the rat hippocampus and striatum, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 19 (1995) 323-332.
35. McCreadie, R.G. and The British Isles Raclopride Study Group, A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia, Acta Psychiatry Scand., 86 (1992) 391-398.
36. i values, J. Pharmacol. Exp. Ther., 251 (1989) 238-246.
37. Meltzer, H.Y. and Nash, J.F., VII. Effects of antipsychotic drugs on serotonin receptors, Pharmacol. Rev., 43 (1991) 587-604.
38. 14C-plastic standards for quantitative autoradiography using LKB Ultrofilm or Amersham Hyperfilm, Neurosci. Lett., 121 (1991) 211-214.
39. Moghaddam, B. and Bunney, B.S., Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study, J. Neurochem., 54 (1990) 1755-1760.
40. Moghaddam, B. and Bunney, B.S., Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs, Prog. Neuro-Psychopharmacol. Biol. Psychiat., 14 (1990) S51-S57.
41. Nawa, H., Kotani, H. and Nakanishi, S., Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing, Nature, 312 (1984) 729-734.
42. Nomikos, G.G., Iurlo, M. Andersson, J.L., Kimura, K. and Svensson, T.H., Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex, Psychopharmacology, 115 (1994) 147-156.
43. Nomikos, G.G., Tham, C.-S., Fibiger, H.C. and Svensson, T.H., The putative antipsychotic drug amperozide preferentially increases c-fos expression in the rat medial prefrontal cortex and the lateral septum, Neuropsychopharmacology, (1996) submitted.
44. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol, Psychopharmacology, 106 (1992) 433-438.
45. 2 receptor occupancy in clozapine treated patients demonstrated by PET, Psychopharmacology, 110 (1993) 365-367.
46. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions, Psychopharmacology, 90 (1986) 287-294.
47. Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, Sydney, Australia, 1986.
48. Radke, J.M., MacLennan, A.J., Vincent, S.R. and Fibiger, H.C., Comparison between short- and long-term haloperidol administration on somatostatin and substance P concentrations in the rat brain, Brain Res., 445 (1988) 55-60.
49. Riley, L.A., Jonakait, G.M. and Hart, R.P., Serotonin modulates the levels of mRNAS coding for thyrotropin-releasing hormone and preprotachykinin by different mechanisms in medullary raphe neurons, Mol. Brain Res., 17 (1993) 251-257.
50. Robertson, G.S. and Fibiger, H.C., Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine, Neuroscience, 46 (2) (1992) 315-328.
51. Robertson, G.S., Matsumura, H. and Fibiger, H.C., Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity, J. Pharmacol. Exp. Ther., 271 (1994) 1058-1066.
52. Salin, P., Mercugliano, M. and Chesselet, M.F., Differential effects of chronic treatment with haloperidol and clozapine on the level of preprosomatostatin mRNA in the striatum, nucleus accumbens, and frontal cortex of the rat, Cell. Mol. Neurobiol., 10 (1990) 127-144.
53. Seeman, P., Brain dopamine receptors, Pharmacol. Rev., 32 (1980) 229-313.
54. Svartengren, J. and Simonsson, P., Receptor binding properties of amperozide, Pharmacol. Toxicol. (Suppl. 1) (1990) 8-11.
55. 3 receptors, Eur. J. Pharmacol., 263 (1994) 235-243.
56. Walker, P.D., Riley, L.A., Hart, R.P. and Jonakait, G.M., Serotonin regulation of tachykinin biosynthesis in the rat neostriatum, Brain Res., 546 (1991) 33-39.
57. Walker, P.D., Riley, L.A., Hart, R.P. and Jonakait, G.M., Serotonin regulation of neostriatal tachykinins following neonatal 6-hydroxydopamine lesions, Brain Res., 557 (1991) 31-36.
58. 3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity, J. Neural Transm. - Gen. Sect., 94 (1993) 11-19.
59. Zachrisson, O., Mathé, A.A., Stenfors, C. and Lindefors, N., Limbic effects of repeated electroconvulsive stimulation on neuropeptide Y and somatostatin mRNA expression in the rat brain, Mol. Brain Res., 31 (1995) 71-85.